Zealand Pharma A/S reports developments tied to its biotechnology business in peptide-based medicines and metabolic health. Company news includes clinical and preclinical updates for obesity, overweight, type 2 diabetes, and related metabolic disease programs, including Zealand-invented candidates such as BI 456906, dapiglutide, ZP8396, and ZP6590.
Recurring announcements also cover strategic collaborations and license agreements with pharmaceutical and biotechnology partners, presentations at medical meetings, quarterly results communications, registered capital increases, share and voting-right updates, and major shareholder notifications under Danish capital markets rules.
Generate Biomedicines (GENB) entered a collaboration and license agreement with Zealand Pharma to develop protein therapeutics, receiving $30 million upfront.
The collaboration initially covers two programs for obesity and other metabolic diseases, with an option to add a third. The companies intend to design proteins with multiple biological functions using Generate’s generative AI platform and Zealand’s metabolic-health expertise. Generate will lead research through selection of lead candidates; Zealand will handle subsequent clinical development, regulatory submissions and worldwide commercialization.
Generate is eligible for up to nearly $1.2 billion in total milestones, including up to $35 million in early preclinical milestones, plus potential development, regulatory and commercial milestones. It will also receive tiered royalties on future worldwide net sales of any commercialized collaboration products.
OTR Therapeutics and Zealand Pharma (Nasdaq: ZEAL) announced a multi-program strategic collaboration on December 11, 2025 to discover and develop oral small-molecule therapeutics for metabolic diseases.
Key commercial terms include an upfront payment of USD 20 million to OTR (potentially increasing to USD 30 million), eligibility for preclinical, development, regulatory and commercial milestone payments, a potential total consideration of ~USD 2.5 billion (majority commercial milestones), and tiered single-digit royalties on worldwide net sales. OTR will lead discovery and preclinical work; Zealand will lead clinical development, regulatory submissions, and commercialization worldwide.
Summary not available.
Zealand Pharma has announced a conference call scheduled for November 10, 2022, at 4 pm CET (10 am ET). The call will follow the release of the third quarter results for 2022. Key executives, including Adam Steensberg and Henriette Wennicke, will present insights and answer questions. Zealand Pharma specializes in peptide-based medicines, with over 10 drug candidates in clinical development. The event will be accessible via registration and will also be available as a recording on Zealand’s Investor website.
Zealand Pharma (Nasdaq: ZEAL) announced its presentations at the Obesity Society Annual Meeting in San Diego, showcasing significant clinical and preclinical research. Key highlights include data from a Phase 2 trial of the GCGR/GLP-1R dual agonist BI 456906, which showed body weight reductions of up to 9% in patients with type 2 diabetes after 16 weeks. The company will also present preclinical results on its peptide candidates, including dapiglutide, ZP8396, and ZP6590, all demonstrating potential for obesity treatment.
Zealand Pharma A/S announces its total number of shares and voting rights as of October 31, 2022, in compliance with the Danish Capital Markets Act. Following a recent increase in share capital due to a private placement of 4,975,000 new shares, Zealand now has a total of 51,513,186 shares, which equals the same number for voting rights and share capital. This reflects Zealand's ongoing focus on developing innovative peptide-based medicines, with several drug candidates advancing in clinical development.
Zealand Pharma (Nasdaq: ZEAL) received a notification from major shareholder Polar Capital on October 11, 2022. As of October 10, Polar Capital holds 5,930,317 shares, representing 11.51% of Zealand's total share capital and voting rights. Zealand Pharma is a biotechnology company focused on developing innovative peptide-based medicines, with a successful portfolio of drug candidates, including two on the market and three in late-stage development.
Zealand Pharma (Nasdaq: ZEAL) has announced a significant shareholder update on October 10, 2022. Van Herk Investments B.V. now holds 7,630,244 shares, representing 14.81% of Zealand’s total share capital and voting rights as of October 7, 2022. The announcement details the ownership structure, indicating that Van Herk Investments is ultimately controlled by Mr. Adrianus van Herk. Zealand Pharma continues to focus on developing peptide-based medicines, with multiple drug candidates in clinical development.
Zealand Pharma announced the registration of a capital increase through the issuance of 4,975,000 new shares, raising approximately DKK 786 million. Following this increase, Zealand’s share capital will reach DKK 51,513,186 with a nominal value of DKK 1 per share. The new shares will be admitted for trading on Nasdaq Copenhagen on 10 October 2022. This move aims to support the company's growth in developing innovative peptide-based medicines. The shares rank equally with existing shares concerning voting and dividend rights.
Zealand Pharma announced the completion of a directed issue and private placement of 4,975,000 new ordinary shares at a subscription price of DKK 158 each, raising approximately DKK 786 million. The offering targets institutional and professional investors and aims to support the development of Zealand's peptide-based therapeutics, particularly the Phase 3 trial of glepaglutide for Short Bowel Syndrome. The New Shares are expected to be listed on Nasdaq Copenhagen on October 10, 2022, with a 90-day lock-up period for management. The funds are projected to extend the company's cash runway until Q2 2024.